Shenzhen Neptunus Bioengineering Co., Ltd.

Total Valuation

Shenzhen Neptunus Bioengineering Co., Ltd. carries a market capitalization of 4.74B, placing it among publicly traded companies globally. Its enterprise value stands at 14.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Shenzhen Neptunus Bioengineering Co., Ltd. currently has 2.63B shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.23, and the price-to-book ratio stands at -24.41.

Enterprise Valuation

On an enterprise value basis, Shenzhen Neptunus Bioengineering Co., Ltd. trades at an EV/EBITDA multiple of 44.38 and an EV/FCF ratio of 16.56. The EV/Sales ratio of 0.52 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 44.38 provides insight into valuation relative to core operating earnings.

Financial Position

Shenzhen Neptunus Bioengineering Co., Ltd. maintains a current ratio of 1.02, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 361.50, indicating elevated leverage, while an interest coverage ratio of 0.45 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Shenzhen Neptunus Bioengineering Co., Ltd. has paid 53.71M in income taxes, reflecting an effective tax rate of 193.72.

Stock Price Statistics

Shenzhen Neptunus Bioengineering Co., Ltd.'s stock has declined approximately -32.58427% over the past 52 weeks. The 50-day moving average sits at 1.97, while the 200-day moving average is 3.00.

Income Statement

Over the trailing twelve months, Shenzhen Neptunus Bioengineering Co., Ltd. generated 28.00B in revenue and converted that into -1.21B in net income, yielding earnings per share of -0.46. EBITDA reached 327.01M, while operating income came in at 327.01M.

Balance Sheet

Shenzhen Neptunus Bioengineering Co., Ltd. holds 3.19B in cash and equivalents against 10.30B in total debt, resulting in a net debt position of 7.03B. Total book value stands at -261.23M, with working capital of 544.64M providing operational flexibility.

Cash Flow

After subtracting -111.80M in capital expenditures, free cash flow totaled -111.80M - equivalent to -0.04 per share.

Margins

Shenzhen Neptunus Bioengineering Co., Ltd. operates with a gross margin of 9.04, reflecting its pricing power and cost economics. The operating margin of 1.17 and net profit margin of -4.31 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -36.14 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Shenzhen Neptunus Bioengineering Co., Ltd.'s most recent stock split took place on May 27, 2016 with a 2:5 split ratio.

Scores

Shenzhen Neptunus Bioengineering Co., Ltd. posts an Altman Z-Score of 1.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.